Cara Therapeutics Announces 2024 Annual Meeting of Stockholders

TL;DR

<b>Cara Therapeutics will host its 2024 Annual Meeting of Stockholders virtually on June 4, 2024, utilizing a webcast and 'Notice and Access' for proxy materials.</b>

AI Summary

Cara Therapeutics, Inc. (TVRD) filed a Proxy Statement (DEF 14A) with the SEC on April 22, 2024. Cara Therapeutics, Inc. will hold its 2024 Annual Meeting of Stockholders virtually on June 4, 2024, at 12:00 p.m. EDT. The meeting will be accessible via live webcast at www.virtualshareholdermeeting.com/CARA2024. The company is using the 'Notice and Access' method for providing proxy materials, mailing a Notice of Internet Availability of Proxy Materials. Stockholders can vote via the internet, telephone, or by requesting paper copies of materials. The proxy statement details the items to be addressed at the Annual Meeting.

Why It Matters

For investors and stakeholders tracking Cara Therapeutics, Inc., this filing contains several important signals. The virtual meeting format aims to improve access, communication, and reduce costs compared to in-person meetings. The 'Notice and Access' method for proxy materials is intended to provide convenient access and reduce printing/distribution costs while conserving resources.

Risk Assessment

Risk Level: low — Cara Therapeutics, Inc. shows low risk based on this filing. The filing is a routine proxy statement (DEF 14A) for an annual meeting, containing standard disclosures and no immediate material financial or operational news.

Analyst Insight

Review the proxy statement for details on proposals, executive compensation, and voting procedures to make an informed decision before the June 4th meeting.

Key Numbers

• 2024 — Annual Meeting Year (2024 Annual Meeting of Stockholders)
• June 4 — Meeting Date (Tuesday, June 4, 2024)
• 12:00 p.m. EDT — Meeting Time (12:00 p.m., Eastern Daylight Time)

Key Players & Entities

• Cara Therapeutics, Inc. (company) — Registrant name
• June 4, 2024 (date) — Date of Annual Meeting
• 12:00 p.m. Eastern Daylight Time (time) — Time of Annual Meeting
• www.virtualshareholdermeeting.com/CARA2024 (url) — Webcast link for the meeting
• Securities Exchange Act of 1934 (regulation) — Act under which proxy statement is filed
• DEF 14A (form_type) — Filing form type

FAQ

Industry Context

Cara Therapeutics, Inc. operates in the pharmaceutical preparations industry, focusing on developing and commercializing innovative therapies for pain and pruritus.

Regulatory Implications

The filing is made under Section 14(a) of the Securities Exchange Act of 1934, requiring specific disclosures for proxy solicitations related to annual meetings.

What Investors Should Do

1. Review the proxy statement for details on proposals to be voted on at the Annual Meeting.
2. Examine executive compensation details and any proposed changes.
3. Understand the voting procedures and deadlines for proxy submission.

Key Dates

• 2024-06-04: 2024 Annual Meeting of Stockholders — Key date for stockholder voting and participation.
• 2024-04-22: Filing Date — Date the Definitive Proxy Statement was filed with the SEC.

Year-Over-Year Comparison

This filing is a DEF 14A (Definitive Proxy Statement) for the 2024 Annual Meeting, following the standard proxy filing schedule.

Filing Documents

• tm242755-1_def14a.htm (DEF 14A) — 935KB
• bc_companytsr-4c.jpg (GRAPHIC) — 72KB
• bc_netincome-4c.jpg (GRAPHIC) — 64KB
• lg_caratmtherap-4c.jpg (GRAPHIC) — 20KB
• px_24caratheraproxy1pg01-bw.jpg (GRAPHIC) — 310KB
• px_24caratheraproxy1pg02-bw.jpg (GRAPHIC) — 228KB
• 0001104659-24-049971.txt (&nbsp;) — 1855KB

Executive Compensation

Executive Compensation 23 Responsible Executive Compensation Practices 23 Compensation Mix 23 2023 Summary Compensation Table 24 Narrative Disclosure to 2023 Summary Compensation Table 25

Executive Compensation Elements

Executive Compensation Elements 25 Outstanding Equity Awards at 2023 Fiscal-Year End 29 401(k) Plan 30 Pay-Versus-Performance Disclosure 30 Securities Authorized For Issuance Under Equity Compensation Plans 34 2019 Inducement Plan 34 2014 Equity Incentive Plan 34 Proposal 3 Ratification Of Selection Of Independent Registered Public Accounting Firm 36 Independent Registered Public Accounting Firm's Fees 37 Pre-Approval Policies and Procedures 37

Security Ownership Of Certain Beneficial Owners and Management

Security Ownership Of Certain Beneficial Owners and Management 38 Transactions With Related Persons 40 Related Person Transactions Policy and Procedures 40 Certain Related Person Transactions 40 i TABLE OF CONTENTS Page Transactions With Vifor (International) Ltd. 40 Transactions With Vifor Fresenius Medical Care Renal Pharma Ltd. 41 Indemnification Agreements with Executive Officers and Directors 42 Proposal 4 Authorized Shares Increase 44 Proposal 5 A Reverse Stock Split and Authorized Shares Reduction 45 Householding Of Proxy Materials 55 Other Matters 55 Appendix A–Form Of Amendment To Certificate Of Incorporation With Respect To Proposal 4 A-1 Appendix B–Form Of Amendment To Certificate Of Incorporation With Respect To Proposal 5 B-1 ii TABLE OF CONTENTS CARA THERAPEUTICS, INC. 400 Atlantic Street Suite 500 Stamford, CT 06901 PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS To Be Held On June 4, 2024 at 12:00 p.m., Eastern Daylight Time QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING Why did I receive a notice regarding the availability of proxy materials on the internet? Pursuant to rules adopted by the Securities and Exchange Commission (the "SEC"), we have elected to provide access to our proxy materials over the internet. Accordingly, we have sent you a Notice of Internet Availability of Proxy Materials (the "Notice") because the Board of Directors (the "Board") of Cara Therapeutics, Inc. (the "Company" or "Cara") is soliciting your proxy to vote at the 2024 Annual Meeting of Stockholders of the Company (the "Annual Meeting"), including at any adjournments or postponements of the meeting. All stockholders will have the ability to access the proxy materials on the website referred to in the Notice or request to receive a printed set of the proxy materials. Instructions on how to access the proxy materials over the internet or to request a printed copy may

View Full Filing

View this DEF 14A filing on SEC EDGAR